Equities

Kyorin Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments13,98519,39427,494
Total Receivables, Net47,69947,25041,636
Total Inventory53,40048,02542,217
Prepaid expenses------
Other current assets, total4,1564,3615,029
Total current assets119,240119,030116,376
Property, plant & equipment, net28,95025,83424,334
Goodwill, net------
Intangibles, net5,0885,3933,289
Long term investments22,10622,97925,703
Note receivable - long term----0
Other long term assets1,7781,4931,439
Total assets177,627176,045171,924
LIABILITIES
Accounts payable14,26513,76210,896
Accrued expenses2,1982,1822,295
Notes payable/short-term debt10,10010,10010,100
Current portion long-term debt/capital leases10,200506529
Other current liabilities, total8,7288,4338,362
Total current liabilities45,49134,98332,182
Total long term debt43510,84311,177
Total debt20,73521,44921,806
Deferred income tax181--175
Minority interest------
Other liabilities, total7854,7583,883
Total liabilities46,89250,58447,417
SHAREHOLDERS EQUITY
Common stock700700700
Additional paid-in capital4,7524,7524,752
Retained earnings (accumulated deficit)136,726134,396132,710
Treasury stock - common(17350)(17666)(17671)
Unrealized gain (loss)5,9265,6956,268
Other equity, total(19)(2416)(2252)
Total equity130,735125,461124,507
Total liabilities & shareholders' equity177,627176,045171,924
Total common shares outstanding575757
Treasury shares - common primary issue7.167.307.31
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.